[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AU2001244675A1 - Aids virus vaccine with the use of sendai virus vector - Google Patents

Aids virus vaccine with the use of sendai virus vector

Info

Publication number
AU2001244675A1
AU2001244675A1 AU2001244675A AU4467501A AU2001244675A1 AU 2001244675 A1 AU2001244675 A1 AU 2001244675A1 AU 2001244675 A AU2001244675 A AU 2001244675A AU 4467501 A AU4467501 A AU 4467501A AU 2001244675 A1 AU2001244675 A1 AU 2001244675A1
Authority
AU
Australia
Prior art keywords
aids
sendai
vaccine
virus
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001244675A
Inventor
Mamoru Hasegawa
Munehide Kano
Atsushi Kato
Tetsuro Matano
Yoshiyuki Nagai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dnavec Research Inc
National Institute of Infectious Diseases
Original Assignee
Agency of Industrial Science and Technology
Dnavec Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency of Industrial Science and Technology, Dnavec Research Inc filed Critical Agency of Industrial Science and Technology
Publication of AU2001244675A1 publication Critical patent/AU2001244675A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18841—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18843—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18871—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2001244675A 2000-03-30 2001-03-30 Aids virus vaccine with the use of sendai virus vector Abandoned AU2001244675A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19312700P 2000-03-30 2000-03-30
US60193127 2000-03-30
PCT/JP2001/002769 WO2001072340A1 (en) 2000-03-30 2001-03-30 Aids virus vaccine with the use of sendai virus vector

Publications (1)

Publication Number Publication Date
AU2001244675A1 true AU2001244675A1 (en) 2001-10-08

Family

ID=22712366

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001244675A Abandoned AU2001244675A1 (en) 2000-03-30 2001-03-30 Aids virus vaccine with the use of sendai virus vector

Country Status (8)

Country Link
US (2) US20020002143A1 (en)
EP (1) EP1270016A4 (en)
JP (2) JPWO2001072340A1 (en)
KR (2) KR20070094989A (en)
CN (1) CN1248740C (en)
AU (1) AU2001244675A1 (en)
HK (1) HK1046243B (en)
WO (1) WO2001072340A1 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE470704T1 (en) * 1995-11-01 2010-06-15 Dnavec Research Inc RECOMBINANT SENDAI VIRUS
US7226786B2 (en) * 1999-05-18 2007-06-05 Dnavec Research Inc. Envelope gene-deficient Paramyxovirus vector
US20030166252A1 (en) * 1999-05-18 2003-09-04 Kaio Kitazato Paramyxovirus-derived RNP
AU6872000A (en) * 1999-09-06 2001-04-10 Dnavec Research Inc. Paramyxoviruses having modified transcription initiation sequence
US7314614B1 (en) 1999-11-02 2008-01-01 Dnavec Research, Inc. Recombinant sendai virus vector for introducing exogenous genes to airway epithelia
EP1251174A4 (en) * 2000-01-19 2003-05-02 Dnavec Research Inc Use of paramyxovirus vector in gene transfer into blood vessel
CN100531802C (en) * 2000-06-01 2009-08-26 株式会社载体研究所 Pseudo-type retrovirus vector containing membrane protein having hemagglutinin activity
CA2414077A1 (en) * 2000-06-27 2002-01-03 Dnavec Research Inc. Virus vector for introducing gene into renal cells
EP1333088A4 (en) * 2000-10-06 2004-11-24 Dnavec Research Inc Paramyxovirus vectors for introducing foreign genes into skeletal muscle
JP2002142770A (en) * 2000-11-08 2002-05-21 Dnavec Research Inc Paramyxovirus vector for transporting gene to circulatory system
WO2003092738A1 (en) * 2002-04-30 2003-11-13 Dnavec Research Inc. Drug- or gene-carrier composition having lowered hemagglutinin activity
EP1548101A4 (en) * 2002-09-04 2006-05-10 Dnavec Research Inc Methods of producing a viral vector comprising a membrane protein that binds to sialic acid as a component of the envelope using neuraminidase derived from gram-positive bacteria
KR20050062634A (en) * 2002-10-24 2005-06-23 가부시키가이샤 디나벡크 겐큐쇼 Method of transferring gene into t cells
ATE459707T1 (en) * 2003-06-30 2010-03-15 Dnavec Research Inc NEGATIVE STRAND RNA VIRUS VECTORS CARRYING A GENE WITH ALTERED HYPERMUTATIBLE REGIONS
US20070269414A1 (en) * 2003-11-04 2007-11-22 Shinji Okano Method for Producing Gene Transferred Denritic Cells
KR20070004637A (en) * 2004-01-22 2007-01-09 가부시키가이샤 디나벡크 겐큐쇼 Process for producing virus vector
EP1775343A4 (en) * 2004-06-24 2007-11-14 Dnavec Research Inc Anticancer agent containing dendritic cell having rna virus transferred thereinto
US8643595B2 (en) * 2004-10-25 2014-02-04 Sipix Imaging, Inc. Electrophoretic display driving approaches
JP4903159B2 (en) * 2005-04-20 2012-03-28 ディナベック株式会社 A highly safe intranasal gene vaccine for the treatment of Alzheimer's disease
AU2006237903A1 (en) * 2005-04-20 2006-10-26 Dna Vec Corporation Highly safe intranasally administrable gene vaccines for treating Alzheimer's disease
AU2006258655A1 (en) * 2005-06-14 2006-12-21 Dnavec Corporation Method for production of antibody
SI1950307T1 (en) * 2005-10-28 2016-02-29 Id Pharma Co., Ltd. Gene transfer into airway epithelial stem cell by using lentiviral vector pseudotyped with rna virus spike protein
US20100167341A1 (en) * 2006-01-17 2010-07-01 Dnavec Corporation Novel protein expression system
US20090257982A1 (en) * 2008-04-11 2009-10-15 Scheiber Lane Bernard medical device for treating diabetes mellitus, obesity, chronic fatigue, aging, and other medical conditions by utilizing modified virus virions to insert messenger ribonucleic acid molecules into cells
US20090257983A1 (en) * 2008-04-11 2009-10-15 Scheiber Lane Bernard Medical treatment device for treating aids by utilizing modified human immunodeficiency virus virions to insert anti-viral medications into t-helper cells
US20090258879A1 (en) * 2008-04-12 2009-10-15 Scheiber Lane Bernard Method for treating cancer, rheumatoid arthritis and other medical diseases by utilizing modified virus virions to insert medications into targeted cells
US20120088819A1 (en) * 2008-10-31 2012-04-12 Makoto Inoue Method for enhancing expression of recombinant protein
US9460666B2 (en) * 2009-05-11 2016-10-04 E Ink California, Llc Driving methods and waveforms for electrophoretic displays
JPWO2012053646A1 (en) * 2010-10-22 2014-02-24 国立大学法人北海道大学 Virus vector for prime / boost vaccine consisting of vaccinia virus vector and Sendai virus vector
PT2702159T (en) 2011-04-28 2018-10-30 St Jude Childrens Res Hospital Modified sendai virus vaccine and imaging vector
CN103193865B (en) * 2013-03-22 2014-09-17 中国医学科学院医学实验动物研究所 Sendai virus antigen peptide and application thereof in Sendai virus infection detection
CN103159859B (en) * 2013-03-22 2014-03-12 中国医学科学院医学实验动物研究所 Sendai virus antigen peptide composition and application thereof in detecting Sendai virus infection
JP2017534284A (en) * 2014-10-27 2017-11-24 インターナショナル エイズ バクシーン イニシアティブ Genetically stable replicable Sendai virus vector containing and expressing an optimized HIV gene
CN106063932B (en) * 2015-04-20 2021-07-13 上海市公共卫生临床中心 Anti-mycobacterium tuberculosis vaccine using sendai virus as vector
US11103574B2 (en) 2016-11-17 2021-08-31 Japan, as represented by the Director-General of National Institute of Infectious Disease Infectious disease vaccine using non-infectious paramyxovirus particle

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5871746A (en) * 1990-12-18 1999-02-16 Institut National De La Sainte Et De La Recherche Medicale (Inserm) Cytotoxic T lymphocyte-inducing lipopeptides and use as vaccines
US6300090B1 (en) 1994-07-29 2001-10-09 The Rockefeller University Methods of use of viral vectors to deliver antigen to dendritic cells
EP0864645B9 (en) * 1995-10-31 2006-03-22 Dnavec Research Inc. Negative-strand rna virus vector having autonomously replicating activity
ATE470704T1 (en) * 1995-11-01 2010-06-15 Dnavec Research Inc RECOMBINANT SENDAI VIRUS
JP2000504585A (en) * 1996-02-13 2000-04-18 フレッド ハッチンソン カンサー リサーチ センター 10A1 retroviral packaging cells and uses thereof
US6828138B1 (en) * 1998-08-11 2004-12-07 Dnavec Research Inc. Recombinant sendai virus vector including a gene encoding a chemokine
CA2360347C (en) 1998-12-31 2013-05-07 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
JP2000253876A (en) 1999-03-08 2000-09-19 Dnavec Research Inc Vaccine using sendai virus vector, and vaccine protein
CA2368948C (en) 1999-05-18 2013-12-24 Dnavec Research Inc. Envelope gene-deficient virus vector of paramyxoviridae
US20030166252A1 (en) * 1999-05-18 2003-09-04 Kaio Kitazato Paramyxovirus-derived RNP
US20020169306A1 (en) * 1999-05-18 2002-11-14 Kaio Kitazato Envelope gene-deficient paramyxovirus vector
US7226786B2 (en) * 1999-05-18 2007-06-05 Dnavec Research Inc. Envelope gene-deficient Paramyxovirus vector
EP1067179A1 (en) 1999-07-09 2001-01-10 Pierre Fabre Medicament Method to select attenuated paramyxoviridae useful for vaccines and therapeutics
AU6872000A (en) 1999-09-06 2001-04-10 Dnavec Research Inc. Paramyxoviruses having modified transcription initiation sequence
US7314614B1 (en) * 1999-11-02 2008-01-01 Dnavec Research, Inc. Recombinant sendai virus vector for introducing exogenous genes to airway epithelia
EP1251174A4 (en) * 2000-01-19 2003-05-02 Dnavec Research Inc Use of paramyxovirus vector in gene transfer into blood vessel
CA2322057A1 (en) * 2000-05-18 2001-11-18 Dnavec Research Inc. Paramyxovirus vectors used for transfer of foreign genes
CN100531802C (en) * 2000-06-01 2009-08-26 株式会社载体研究所 Pseudo-type retrovirus vector containing membrane protein having hemagglutinin activity
CA2414077A1 (en) * 2000-06-27 2002-01-03 Dnavec Research Inc. Virus vector for introducing gene into renal cells
EP1333088A4 (en) 2000-10-06 2004-11-24 Dnavec Research Inc Paramyxovirus vectors for introducing foreign genes into skeletal muscle
JP2002142770A (en) 2000-11-08 2002-05-21 Dnavec Research Inc Paramyxovirus vector for transporting gene to circulatory system
ATE393235T1 (en) 2000-11-27 2008-05-15 Dnavec Research Inc PARAMYXOVIRUS VECTOR ENCODING FIBROBLAST GROWTH FACTOR 2 (FGF2) AND USE THEREOF
US20040265272A1 (en) * 2001-09-28 2004-12-30 Aikichi Iwamoto Mammalian cell-infecting virus vector encoding epitope-bound beta2m and utilization thereof
US20070269414A1 (en) * 2003-11-04 2007-11-22 Shinji Okano Method for Producing Gene Transferred Denritic Cells
EP1775343A4 (en) * 2004-06-24 2007-11-14 Dnavec Research Inc Anticancer agent containing dendritic cell having rna virus transferred thereinto
AU2006237903A1 (en) * 2005-04-20 2006-10-26 Dna Vec Corporation Highly safe intranasally administrable gene vaccines for treating Alzheimer's disease
WO2007139178A1 (en) 2006-05-31 2007-12-06 Dnavec Corporation Therapeutic agent for alzheimer's disease

Also Published As

Publication number Publication date
HK1046243A1 (en) 2003-01-03
KR20020086207A (en) 2002-11-18
EP1270016A1 (en) 2003-01-02
JPWO2001072340A1 (en) 2004-01-08
CN1362885A (en) 2002-08-07
EP1270016A4 (en) 2005-10-19
KR100854917B1 (en) 2008-08-27
CN1248740C (en) 2006-04-05
KR20070094989A (en) 2007-09-27
JP2012144541A (en) 2012-08-02
US20100266633A1 (en) 2010-10-21
WO2001072340A1 (en) 2001-10-04
US8217019B2 (en) 2012-07-10
HK1046243B (en) 2006-08-18
US20020002143A1 (en) 2002-01-03

Similar Documents

Publication Publication Date Title
AU2001244675A1 (en) Aids virus vaccine with the use of sendai virus vector
AU2001247902A1 (en) Cpg reduced plasmids and viral vectors
AU2002336760A1 (en) Mutable vaccines
AU2002234643A1 (en) Amphoteric liposomes and the use thereof
AU2002219135A1 (en) Substituted 2-anilino-benzimidazoles and the use thereof as NHE-inhibitors
AU2001292125A1 (en) Genetic factors affecting the outcome of viral infections
EP1234023A4 (en) Membrane virus host range mutations and their uses as vaccine substrates
AU2913400A (en) Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof
AU2002347464A1 (en) Anti-arthropod vector vaccines methods of selecting and uses thereof
AU2002220416A1 (en) Oncolytic virus
AU2001285827A1 (en) Use of strains of the parapox ovis virus against organ fibrosis
AU2001285827A2 (en) Use of strains of the parapox ovis virus against organ fibrosis
GB2383752B (en) Use of strains of the parapox ovis virus against organ fibrosis
AU2002320079A1 (en) Vaccines, immunotherapeutics and methods of using the same
AU2001233588A1 (en) New toralactone and its derivation and the use of decreasing blood-fat and losing weight
AU4957800A (en) Vaccine against isa virus
AU2003246485A1 (en) Interactions of the epstein-barr virus protein ebna1, and uses thereof
AU2002222139A1 (en) Hcv vaccines
AU2002236065A1 (en) Papillomavirus vaccines
AU2002224845A1 (en) Viral expression system
AU2002217863A1 (en) Homing peptide multimers, their preparation and uses
AU2691400A (en) Virus vector
AU2002258268A1 (en) Sivmac239 immunogenic plasmids and aids dna vaccine containing the same
AU2001266534A1 (en) Papillomavirus vaccine
AU2001271767A1 (en) The nip3 family of proteins